Blood transfusion: preoperative considerations and complications

doi:10.1017/CBO9780511920660.026

Chapter 23 - Blood transfusion: preoperative considerations and complications

from Section 6 - Hematology

Published online by Cambridge University Press: 05 September 2013

Julie Katz Karp ,

Christopher D. Hillyer and

Edited by

Thomas F. Dodson and

Michael F. Lubin: Affiliation:
Emory University, Atlanta
Thomas F. Dodson: Affiliation:
Emory University, Atlanta
Neil H. Winawer: Affiliation:
Emory University, Atlanta

Book contents

Get access

Summary

Introduction

In the USA, blood transfusion is the most common procedure performed in hospitals [1]. Component therapy is the preferred method of blood administration, as it allows blood transfusion to be individualized to the patient's specific needs. Blood components include red cells, platelets, plasma, and cryoprecipitate. Although transfusion is often essential to effective patient care, it is not without risk. Blood transfusion is associated with multiple adverse outcomes, including both non-infectious and infectious complications. Thus, benefits and risks of transfusion must be considered for each patient.

Maximum surgical blood order

A maximum surgical blood order schedule (MSBOS) is used to predict surgical blood needs and to reserve blood products for transfusion for surgery. A MSBOS is created by reviewing institutional blood utilization for each type of surgical procedure and usually set at the number of products required for 80–90% of the procedures. The MSBOS will dictate if either a type and screen (T/S) or a type and cross (T/C) is indicated, as well as the number and type of blood products to be reserved for a particular surgical procedure.

Type: Chapter
Information: Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
, pp. 252 - 264

DOI: https://doi.org/10.1017/CBO9780511920660.026 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Agency for Healthcare Research and Quality, Overview of Hospitals. 2003. .

Roback, JD, Combs, MR, Grossman, BJ et al. AABB Technical Manual. 16th edn. Bethesda, MD: AABB; 2008.Google Scholar

Karen, E, King, MD, Gottschall, J et al. Blood Transfusion Therapy: A Physician’s Handbook. 9th edn. Bethesda, MD:AABB; 2008.Google Scholar

Hillyer, CD, Shaz, BH, Zimring, JC, Abshire, TC, eds. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Philadelphia, PA:Elsevier; 2009.

Blajchman, MA.The clinical benefits of the leukoreduction of blood products. J Trauma 2006; 60: s83–90.CrossRef Google Scholar PubMed

Nichols, WG, Price, TH, Gooley, T, Corey, L, Boeckh, M.Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 1010: 4195–220.CrossRef Google Scholar

Schroeder, ML.Transfusion-associated graft-versus-host disease. Br J Haematol 2002; 117: 275–87.CrossRef Google Scholar PubMed

Popovsky, MA.Frozen and washed red blood cells: new approaches and applications. Transfus Apher Sci 2001; 25: 193–4.CrossRef Google Scholar PubMed

Borgman, MA, Spinella, PC, Perkins, JG et al. The ratio of blood products transfused affects morality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 62: 805–13.CrossRef Google Scholar

The National Healthcare Safety Network (NHSN) Manual: Biovigilance Component. Centers for Disease Control and Prevention, June 2011. .

Zou, S, Stramer, SL, Notari, EP et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49: 1609–20.CrossRef Google Scholar PubMed

Commanor, L, Holland, P.Hepatitis B virus blood screening: unfinished agendas. Vox Sanguinis 2006; 91: 1–123.CrossRef Google Scholar

Zou, S, Dorsey, KA, Notari, EP et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495–504.CrossRef Google Scholar

Dodd, RY, Notari, EP, Stramer, SL.Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975–9.CrossRef Google Scholar PubMed

US Food and Drug Administration. Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risks of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components intended for Transfusion. November 2009.

Centers for Disease Control and Prevention. West Nile Virus Transmission via Organ Transplantation and Blood Transfusion – Louisiana, 2008. Morbid Mortal Weekly Rep 2009; 58(45): 1263–7.Google Scholar

Perkins, HA, Busch, MP.Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50: 2080–99.CrossRef Google Scholar PubMed

Young, C, Losikoff, P, Chawla, A, Glasser, L, Forman, E.Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47: 540–4.CrossRef Google Scholar PubMed

AABB Association Bulletin #10–02 – Interim Standard 5.1.5.1.1. .

Benjamin, RJ, Kline, L, Dy, BA et al. Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008; 48(11): 2348–55.CrossRef Google Scholar PubMed

Eder, AF, Kennedy, JM, Dy, B et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004–6). Transfusion 2007; 47: 1134–42.CrossRef Google Scholar